SCHEMBL9101978

SCHEMBL9101978

Cc1ccc2c(c1)Oc1ncccc1C(=O)N2C

nearest known ligand 0.56

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
LMNA P02545 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
POLB P06746 4/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9099840 0.84 MAPT (0.58) MAPTLMNASMN1; SMN2POLBMEN1
SCHEMBL9102280 0.83 TP53 (0.52) MAPTLMNASMN1; SMN2POLBKMT2A
SCHEMBL9103407 0.80 PIK3CD (0.38) MAPTLMNASMN1; SMN2POLBMEN1
SCHEMBL9100124 0.80 NR1H2 (0.40) MAPTLMNASMN1; SMN2POLBMEN1
SCHEMBL9101244 0.76 CASP1 (0.45) LMNAMEN1KMT2A
SCHEMBL9853429 0.75 NR1H2 (0.47) MAPTLMNASMN1; SMN2POLBKMT2A
SCHEMBL9175873 0.72 MAPT (0.58) MAPTLMNASMN1; SMN2POLBMEN1
SCHEMBL9369602 0.71 PIK3CD (0.46) MAPTSMN1; SMN2POLB
SCHEMBL8936588 0.71 MAPT (0.50) MAPTLMNASMN1; SMN2POLBMEN1
SCHEMBL9004267 0.70 NR1H2 (0.47) SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5550122-A INHIBIT REVERSE TRANSCRIPTASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1996-08-27 US disclosed
EP-0415303-B1 Pyrido [2,3-b][1,5]benzoxazepin (and thiazepin)-5(6H)-ones and -thiones and their use in the prevention or treatment of HIV infection BOEHRINGER INGELHEIM PHARMA (US) 1995-12-13 EP disclosed
EP-0415303-A2 Pyrido [2,3-b][1,5]benzoxazepin (and thiazepin)-5(6H)-ones and -thiones and their use in the prevention or treatment of HIV infection BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 1991-03-06 EP disclosed